
Chinese General Practice ›› 2023, Vol. 26 ›› Issue (34): 4308-4314.DOI: 10.12114/j.issn.1007-9572.2022.0562
Special Issue: 内分泌代谢性疾病最新文章合辑; 社区卫生服务最新研究合辑
• Original Research • Previous Articles Next Articles
Received:2022-09-29
Revised:2023-07-16
Published:2023-12-05
Online:2023-08-03
Contact:
MA Xiaojun
通讯作者:
马晓骏
作者简介:基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0562
| 组别 | 例数 | 性别〔例(%)〕 | 年龄( | 糖尿病病程( | 文化程度〔例(%)〕 | 婚姻状况〔例(%)〕 | 医疗保险参保情况〔例(%)〕 | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 男 | 女 | 初中及以下 | 高中 | 大专及以上 | 已婚 | 未婚/离异/丧偶 | 城镇职工基本医疗保险 | 医疗互助帮困对象/城镇居民基本医疗保险 | ||||
| 对照组 | 106 | 50(31.2) | 56(52.8) | 71.3±8.3 | 6.2±2.8 | 72(67.9) | 23(21.7) | 11(10.4) | 92(86.8) | 14(13.2) | 65(61.3) | 41(38.7) |
| 干预组 | 106 | 45(42.5) | 61(57.5) | 70.7±6.4 | 6.7±3.4 | 75(70.8) | 19(17.9) | 12(11.3) | 95(89.6) | 11(10.4) | 58(54.7) | 48(45.3) |
| χ2(t)值 | 0.238 | 0.611a | -1.241a | 0.273 | 0.204 | 0.474 | ||||||
| P值 | 0.490 | 0.542 | 0.216 | 0.460 | 0.535 | 0.330 | ||||||
Table 1 Comparison of baseline data between two groups of diabetes patients
| 组别 | 例数 | 性别〔例(%)〕 | 年龄( | 糖尿病病程( | 文化程度〔例(%)〕 | 婚姻状况〔例(%)〕 | 医疗保险参保情况〔例(%)〕 | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 男 | 女 | 初中及以下 | 高中 | 大专及以上 | 已婚 | 未婚/离异/丧偶 | 城镇职工基本医疗保险 | 医疗互助帮困对象/城镇居民基本医疗保险 | ||||
| 对照组 | 106 | 50(31.2) | 56(52.8) | 71.3±8.3 | 6.2±2.8 | 72(67.9) | 23(21.7) | 11(10.4) | 92(86.8) | 14(13.2) | 65(61.3) | 41(38.7) |
| 干预组 | 106 | 45(42.5) | 61(57.5) | 70.7±6.4 | 6.7±3.4 | 75(70.8) | 19(17.9) | 12(11.3) | 95(89.6) | 11(10.4) | 58(54.7) | 48(45.3) |
| χ2(t)值 | 0.238 | 0.611a | -1.241a | 0.273 | 0.204 | 0.474 | ||||||
| P值 | 0.490 | 0.542 | 0.216 | 0.460 | 0.535 | 0.330 | ||||||
| 组别 | 例数 | 1个月内FPG监测 | 1个月内2 hPG监测 | 1个月内血糖综合监测a | 6个月内HbA1c监测 | 开展自我血糖监测 | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 干预前 | 干预后 | 干预前 | 干预后 | 干预前 | 干预后 | 干预前 | 干预后 | 干预前 | 干预后 | ||
| 对照组 | 106 | 44(41.5) | 53(50.0) | 41(38.7) | 43(40.6) | 25(23.6) | 28(26.4) | 40(37.7) | 45(42.5) | 16(15.1) | 22(20.8) |
| 干预组 | 106 | 51(48.1) | 101(95.3) | 39(36.8) | 77(72.6) | 24(22.6) | 58(54.7) | 42(39.6) | 89(84.0) | 13(12.3) | 45(42.5) |
| χ2值 | 0.935 | 54.685 | 0.080 | 22.199 | 0.027 | 17.608 | 0.080 | 39.268 | 0.360 | 11.544 | |
| P值 | 0.334 | <0.001 | 0.778 | <0.001 | 0.871 | <0.001 | 0.778 | <0.001 | 0.549 | 0.001 | |
| 组别 | 记录血糖日记 | 规范用药 | 遵医嘱饮食 | 规律运动 | 1年内周围血管并发症筛查 | ||||||
| 干预前 | 干预后 | 干预前 | 干预后 | 干预前 | 干预后 | 干预前 | 干预后 | 干预前 | 干预后 | ||
| 对照组 | 12(11.3) | 14(13.2) | 86(81.1) | 89(84.0) | 83(78.3) | 85(80.2) | 65(61.3) | 66(62.3) | 20(18.9) | 25(23.6) | |
| 干预组 | 15(14.2) | 28(26.4) | 81(76.4) | 101(95.3) | 78(73.6) | 98(92.5) | 59(55.7) | 78(73.6) | 18(17.0) | 56(52.8) | |
| χ2值 | 0.382 | 5.820 | 0.705 | 7.303 | 0.646 | 6.751 | 0.699 | 3.118 | 0.128 | 19.200 | |
| P值 | 0.537 | 0.016 | 0.401 | 0.007 | 0.422 | 0.009 | 0.403 | 0.078 | 0.720 | <0.001 | |
| 组别 | 1年内尿白蛋白/肌酐筛查 | 1年内颈动脉斑块筛查 | 1年内眼底筛查 | 每周足部检查 | |||||||
| 干预前 | 干预后 | 干预前 | 干预后 | 干预前 | 干预后 | 干预前 | 干预后 | ||||
| 对照组 | 29(27.4) | 32(30.2) | 33(31.1) | 32(30.2) | 12(11.3) | 15(14.2) | 26(24.5) | 30(28.3) | |||
| 干预组 | 28(26.4) | 72(67.9) | 31(29.2) | 54(50.9) | 14(13.2) | 44(41.5) | 24(22.6) | 40(37.7) | |||
| χ2值 | 0.024 | 30.199 | 0.090 | 9.469 | 0.175 | 19.751 | 0.105 | 2.133 | |||
| P值 | 0.877 | <0.001 | 0.765 | 0.002 | 0.675 | <0.001 | 0.746 | 0.144 | |||
Table 2 Comparison of cognition and behavior related to diabetes management between the two groups before and after intervention
| 组别 | 例数 | 1个月内FPG监测 | 1个月内2 hPG监测 | 1个月内血糖综合监测a | 6个月内HbA1c监测 | 开展自我血糖监测 | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 干预前 | 干预后 | 干预前 | 干预后 | 干预前 | 干预后 | 干预前 | 干预后 | 干预前 | 干预后 | ||
| 对照组 | 106 | 44(41.5) | 53(50.0) | 41(38.7) | 43(40.6) | 25(23.6) | 28(26.4) | 40(37.7) | 45(42.5) | 16(15.1) | 22(20.8) |
| 干预组 | 106 | 51(48.1) | 101(95.3) | 39(36.8) | 77(72.6) | 24(22.6) | 58(54.7) | 42(39.6) | 89(84.0) | 13(12.3) | 45(42.5) |
| χ2值 | 0.935 | 54.685 | 0.080 | 22.199 | 0.027 | 17.608 | 0.080 | 39.268 | 0.360 | 11.544 | |
| P值 | 0.334 | <0.001 | 0.778 | <0.001 | 0.871 | <0.001 | 0.778 | <0.001 | 0.549 | 0.001 | |
| 组别 | 记录血糖日记 | 规范用药 | 遵医嘱饮食 | 规律运动 | 1年内周围血管并发症筛查 | ||||||
| 干预前 | 干预后 | 干预前 | 干预后 | 干预前 | 干预后 | 干预前 | 干预后 | 干预前 | 干预后 | ||
| 对照组 | 12(11.3) | 14(13.2) | 86(81.1) | 89(84.0) | 83(78.3) | 85(80.2) | 65(61.3) | 66(62.3) | 20(18.9) | 25(23.6) | |
| 干预组 | 15(14.2) | 28(26.4) | 81(76.4) | 101(95.3) | 78(73.6) | 98(92.5) | 59(55.7) | 78(73.6) | 18(17.0) | 56(52.8) | |
| χ2值 | 0.382 | 5.820 | 0.705 | 7.303 | 0.646 | 6.751 | 0.699 | 3.118 | 0.128 | 19.200 | |
| P值 | 0.537 | 0.016 | 0.401 | 0.007 | 0.422 | 0.009 | 0.403 | 0.078 | 0.720 | <0.001 | |
| 组别 | 1年内尿白蛋白/肌酐筛查 | 1年内颈动脉斑块筛查 | 1年内眼底筛查 | 每周足部检查 | |||||||
| 干预前 | 干预后 | 干预前 | 干预后 | 干预前 | 干预后 | 干预前 | 干预后 | ||||
| 对照组 | 29(27.4) | 32(30.2) | 33(31.1) | 32(30.2) | 12(11.3) | 15(14.2) | 26(24.5) | 30(28.3) | |||
| 干预组 | 28(26.4) | 72(67.9) | 31(29.2) | 54(50.9) | 14(13.2) | 44(41.5) | 24(22.6) | 40(37.7) | |||
| χ2值 | 0.024 | 30.199 | 0.090 | 9.469 | 0.175 | 19.751 | 0.105 | 2.133 | |||
| P值 | 0.877 | <0.001 | 0.765 | 0.002 | 0.675 | <0.001 | 0.746 | 0.144 | |||
| 组别 | 例数 | FPG达标率 | 2 hPG达标率 | HbA1c达标率 | ABC综合达标率 | ||||
|---|---|---|---|---|---|---|---|---|---|
| 干预前 | 干预后 | 干预前 | 干预后 | 干预前 | 干预后 | 干预前 | 干预后 | ||
| 对照组 | 106 | 50(47.2) | 37(34.9) | 49(46.2) | 66(62.3) | 51(48.1) | 59(55.7) | 25(23.6) | 28(26.4) |
| 干预组 | 106 | 54(50.9) | 74(69.8) | 49(46.2) | 69(65.1) | 54(50.9) | 74(69.8) | 28(26.4) | 40(37.7) |
| χ2值 | 1.421 | 7.523 | 1.000 | 1.749 | 1.749 | 4.163 | 1.749 | 3.663 | |
| P值 | 0.158 | <0.001 | 0 | 0.083 | 0.083 | <0.001 | 0.083 | <0.001 | |
Table 3 Comparison of key indicator compliance rates between the two groups of patients before and after intervention
| 组别 | 例数 | FPG达标率 | 2 hPG达标率 | HbA1c达标率 | ABC综合达标率 | ||||
|---|---|---|---|---|---|---|---|---|---|
| 干预前 | 干预后 | 干预前 | 干预后 | 干预前 | 干预后 | 干预前 | 干预后 | ||
| 对照组 | 106 | 50(47.2) | 37(34.9) | 49(46.2) | 66(62.3) | 51(48.1) | 59(55.7) | 25(23.6) | 28(26.4) |
| 干预组 | 106 | 54(50.9) | 74(69.8) | 49(46.2) | 69(65.1) | 54(50.9) | 74(69.8) | 28(26.4) | 40(37.7) |
| χ2值 | 1.421 | 7.523 | 1.000 | 1.749 | 1.749 | 4.163 | 1.749 | 3.663 | |
| P值 | 0.158 | <0.001 | 0 | 0.083 | 0.083 | <0.001 | 0.083 | <0.001 | |
| 组别 | 例数 | FPG(mmol/L) | 2 hPG(mmol/L) | HbA1c(%) | |||
|---|---|---|---|---|---|---|---|
| 干预前 | 干预后 | 干预前 | 干预后 | 干预前 | 干预后 | ||
| 对照组 | 106 | 8.9±2.2 | 7.7±1.4a | 10.1±2.2 | 9.2±1.9a | 7.5±1.3 | 7.2±1.0 |
| 干预组 | 106 | 8.3±2.3 | 6.9±1.1a | 10.6±2.3 | 8.9±1.8a | 7.4±1.5 | 6.6±0.9a |
| t值 | -1.807 | -5.101 | 1.300 | -1.392 | -0.451 | -4.528 | |
| P值 | 0.074 | <0.001 | 0.197 | 0.167 | 0.653 | <0.001 | |
Table 4 Comparison of key indicator levels between the two groups of patients before and after intervention
| 组别 | 例数 | FPG(mmol/L) | 2 hPG(mmol/L) | HbA1c(%) | |||
|---|---|---|---|---|---|---|---|
| 干预前 | 干预后 | 干预前 | 干预后 | 干预前 | 干预后 | ||
| 对照组 | 106 | 8.9±2.2 | 7.7±1.4a | 10.1±2.2 | 9.2±1.9a | 7.5±1.3 | 7.2±1.0 |
| 干预组 | 106 | 8.3±2.3 | 6.9±1.1a | 10.6±2.3 | 8.9±1.8a | 7.4±1.5 | 6.6±0.9a |
| t值 | -1.807 | -5.101 | 1.300 | -1.392 | -0.451 | -4.528 | |
| P值 | 0.074 | <0.001 | 0.197 | 0.167 | 0.653 | <0.001 | |
| 组别 | 例数 | 社区诊疗能力良好 | 社区药物基本满足需求a | 社区具备血糖相关指标检测设备 | 社区能解决基本健康问题 | 社区能开展并发症筛查 | 社区专病咨询指导方便 |
|---|---|---|---|---|---|---|---|
| 对照组 | 106 | 69(65.1) | 72(67.9) | 58(54.7) | 72(67.9) | 55(51.9) | 88(83.0) |
| 干预组 | 106 | 92(86.8) | 91(85.8) | 96(90.6) | 89(84.0) | 87(82.1) | 102(96.2) |
| χ2值 | -5.401 | -4.793 | -7.680 | -4.482 | -6.752 | -4.000 | |
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
Table 5 Consultation experiences between the two groups of patients at community health service centers
| 组别 | 例数 | 社区诊疗能力良好 | 社区药物基本满足需求a | 社区具备血糖相关指标检测设备 | 社区能解决基本健康问题 | 社区能开展并发症筛查 | 社区专病咨询指导方便 |
|---|---|---|---|---|---|---|---|
| 对照组 | 106 | 69(65.1) | 72(67.9) | 58(54.7) | 72(67.9) | 55(51.9) | 88(83.0) |
| 干预组 | 106 | 92(86.8) | 91(85.8) | 96(90.6) | 89(84.0) | 87(82.1) | 102(96.2) |
| χ2值 | -5.401 | -4.793 | -7.680 | -4.482 | -6.752 | -4.000 | |
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| [1] |
|
| [2] |
中华医学会糖尿病学分会,国家基层糖尿病防治管理办公室. 国家基层糖尿病防治管理指南(2018)[J]. 中华内科杂志,2018,57(12):885-893. DOI:10.3760/cma.j.issn.0578-1426.2018.12.003.
|
| [3] |
王俊薇,刘云,李连喜. 中国糖尿病管理模式及思考[J]. 中国全科医学,2021,24(24):3019-3025. DOI:10.12114/j.issn.1007-9572.2021.00.551.
|
| [4] | |
| [5] |
|
| [6] |
陈星池. 糖尿病患者健康管理的研究进展[J]. 糖尿病新世界,2017,20(14):195-196.
|
| [7] |
陈杏琼,胡凤琼,黄丽婵. 自我管理小组健康教育模式对社区老年2型糖尿病患者生活质量的影响研究[J]. 临床医学工程,2020,27(3):369-370.
|
| [8] |
周芬芳,徐春蕾,庄毓义,等. 上海市松江区佘山镇社区卫生服务中心老年糖尿病患者综合管理效果评价[J]. 中国慢性病预防与控制,2019,27(5):395-397.
|
| [9] |
叶琪. 糖尿病健康管理模式的研究进展综述[J]. 影像研究与医学应用,2018,2(3):1-3.
|
| [10] |
姚裕忠,龚玮华,钟瑜,等. 基于健康信念模式的自我血糖管理路径的探索与思考[J]. 中国医药指南,2021,19(10):227-228,231. DOI:10.15912/j.cnki.gocm.2021.10.104.
|
| [11] |
王陇德. 健康管理师-基础知识[M]. 北京:人民卫生出版社,2013.
|
| [12] |
中华医学会糖尿病分会. 中国2型糖尿病防治指南(2017年版)[J]. 中华糖尿病杂志,2018,10(1):4-67. DOI:10.3760/cma.j.issn.1674-5809.2018.01.003.
|
| [13] |
上海市卫生和计划生育委员会. 关于转发《国家基本公共卫生服务规范(第三版)》的通知[A/OL]. (2017-06-16)[2022-10-01].
|
| [14] |
中华医学会糖尿病学分会. 中国血糖监测临床应用指南(2015年版)[J]. 糖尿病临床,2016,10(5):205-218. DOI:10.3969/cma.j.issn.1672-7851.2016.05.003.
|
| [15] |
中华医学会糖尿病学分会糖尿病教育与管理学组. 中国2型糖尿病自我管理处方专家共识(2017年版)[J]. 中华糖尿病杂志,2017,9(12):740-750. DOI:10.3760/cma.j.issn.1674-5809.2017.12.004.
|
| [16] |
张瑞英,王敬章,林鲜,等. 精准医学理论在我国全科医师培养中的作用研究[J]. 中国医药导报,2022,19(20):30-32.
|
| [17] |
于晓松,路孝琴. 全科医学概论[M]. 5版. 北京:人民卫生出版社,2018.
|
| [18] |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志,2021,13(4):315-409. DOI:10.3760/cma.j.cn115791-20210221-00095.
|
| [19] |
中华医学会糖尿病学分会. 中国成人2型糖尿病患者糖化血红蛋白控制目标及达标策略专家共识[J]. 中华糖尿病杂志,2020,12(1):1-12. DOI:10.3760/cma.j.issn.1674-5809.2020.01.001.
|
| [20] |
张姗姗. 信息管理系统与同伴教育相结合的管理模式对糖尿病患者自我管理水平及综合指标的影响[J]. 中国卫生工程学,2020,19(2):307-308. DOI:10.19937/j.issn.1671-4199.2020.02.059.
|
| [21] | |
| [22] |
戴蓉. 糖尿病患者自我血糖监测现状、影响因素分析及干预研究[J]. 实用医药杂志,2015,32(9):845-846.
|
| [1] | WANG Yang, ZHAO Shiting, CHEN Yingying, SUN Zilin, QIU Shanhu. Key Points of Exercise Intervention and Implementation for People with Complications of Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(21): 2989-2994. |
| [2] | LI Zhenyu, ZHU Qiong, CHEN Rong, LU Jing, YU Zhijie, SHEN Fulai, SHEN Yi, FENG Yu, LIU Mei. A Single-group Community Intervention Trial on Improving the Service Efficiency of Contracted Residents Via an Enhanced Medical-preventive "Micro" Integration Service Package [J]. Chinese General Practice, 2026, 29(21): 3020-3027. |
| [3] | LI Jiawei, GAO Xinyi, GE Aoqi, LI Juanjuan, YUAN Beibei. Demand and Associated Factors for Integrated Medical Care and Preventive Services among Patients with Type 2 Diabetes [J]. Chinese General Practice, 2026, 29(21): 3028-3039. |
| [4] | PAN Ziyun, YIN Hao, LIN Zhirou, MAO Jingyi, HUANG Yan, LUO Yanhua, XIAO Jiafu, HU Yin. From Mechanism to Therapy: Diabetic Autonomic Neuropathy [J]. Chinese General Practice, 2026, 29(21): 2982-2988. |
| [5] | LI Wenping, CHEN Jianhua, XU Jiapei, JIN Xue, PAN Zihan, CHI Chunhua. A Scoping Review on the Empowerment of Community Elderly Health Services by Digital-Intelligent Health Management Platforms [J]. Chinese General Practice, 2026, 29(21): 2938-2949. |
| [6] | AN Yanhong, WANG Shidong, LI Xiaoran, GUO Jiayang, WANG Zhe, SHA Peilin, MENG Yijun, LI Xiaoxuan, SHI Xue, YU Zexing, XIAO Yonghua. Study on Risk Factors and Nomogram Prediction Model for Diabetic Kidney Disease: Based on Contrast-enhanced Ultrasound Technology [J]. Chinese General Practice, 2026, 29(21): 2995-3003. |
| [7] | YU Haiyan, XIANG Tong, GAO Wenjuan, WU Hao. Research and Application of Digital Health Technologies in Multimorbidity Management [J]. Chinese General Practice, 2026, 29(21): 2933-2937. |
| [8] | GE Dan, WANG Zhi, DING Qun, GUO Tonglan, XU Tongdao. Relationship between Remnant Cholesterol and Non-alcoholic Fatty Liver Disease as well as Progressive Liver Fibrosis in Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(20): 2854-2859. |
| [9] | LI Wanyu, JIN Hua, YANG Sen, FU Qiangqiang, YU Dehua. Assessment and Optimization of Community Health Behaviors Guided by the Behaviour Change Wheel Theory [J]. Chinese General Practice, 2026, 29(19): 2688-2694. |
| [10] | ZHANG Xiaojuan, LIU Yang, PENG Bo, YE Yuan, ZHU Kun. Study on the Prevention and Treatment of Hypertension and Diabetes Mellitus in Community Hospital [J]. Chinese General Practice, 2026, 29(19): 2614-2620. |
| [11] | ZHAO Xinran, WU Yibo, ZHANG Xuxi, CHEN Ping, SUN Xinying. The Current Situation and Influencing Factors of Smart Health Management Services and Devices Utilization among Chinese Adults: a Mixed Methods Study [J]. Chinese General Practice, 2026, 29(19): 2724-2734. |
| [12] | PANG Shu, SUN ying, JIANG Chunyan. Comparison of the Effectiveness of Fried's Frailty Phenotype and the FRAIL Scale in Assessing Pre-frailty among Community-dwelling Older Adults Undergoing Health Examinations [J]. Chinese General Practice, 2026, 29(19): 2664-2670. |
| [13] | ZHAO Xinxin, SUN Xiaoting, LUO Xinhao, SUN Jin, PENG Derong, ZHENG Jialin. Research on the Localization of the Patient-centered Medical Home Model in China: Adaptation Mechanisms, Challenges, and Pathway Analysis [J]. Chinese General Practice, 2026, 29(19): 2608-2613. |
| [14] | JIAN Yingchun, ZENG Yongqin, ZHANG Haiping, WANG Zhengdi, AN Ke, YAN Rui. Recent Advances in Mitochondrial Dysfunction in Chronic Metabolic Diseases [J]. Chinese General Practice, 2026, 29(18): 2577-2584. |
| [15] | MIAO Jingjie, ZHANG Jinwen, WU Qianhao, HAN Peipei. Research Advances on the Effects of Intermittent Fasting on Cardiometabolic Diseases [J]. Chinese General Practice, 2026, 29(18): 2538-2545. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||